Fig. 6: ZK53 exhibits anticancer activity in vivo.
From: Selective activator of human ClpP triggers cell cycle arrest to inhibit lung squamous cell carcinoma
a Therapeutic effect of ZK53 on the tumor growth of H1703 cells in Balb/c nude mice (n = 8 animals). The tumor volume (b) and tumor weight (c) on the day of euthanization (n = 8 animals). d Representative images of hematoxylin and eosin (H&E) staining and Ki67 immunohistochemistry of LUSC tumor tissues. The image shown is a representative of three tests. Scale bar, 100 µm. e Schematic illustration of ZK53 treatment in KL mouse model. f Representative H&E staining and immunohistochemistry staining for TTF1 and p40 in LUAD and LUSC from KL mice treated with vehicle or ZK53. LUAD is indicated by blue dashed line, and LUSC is presented by red dashed line. Scale bar for whole lung: 1 mm; Scale bar for others: 50 µm. g Quantification of ratios of LUAD, LUSC, and normal tissue in whole lungs in KL mice treated with vehicle or ZK53 (n = 6 animals). Representative Ki67 immunostaining (h) and statistical analyses (i) (n = 30 images). Scale bar, 50 µm. The P values were calculated by a two-sided Student’s t test with confidence interval of 95%. Figure 6i is represented as mean ± SD (error bars), and all the other data are represented as mean ± SEM (error bars).
